You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 214 The KRASG12D(ON) covalent tricomplex inhibitor RM-044 increases tumor antigen presentation and TCR repertoire diversity to promote anti-tumor immunity in a preclinical model of KRASG12D mutant cancer

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Biomarkers, Immune Monitoring and Novel Technologies
214 The KRASG12D(ON) covalent tricomplex inhibitor RM-044 increases tumor antigen presentation and TCR repertoire diversity to promote anti-tumor immunity in a preclinical model of KRASG12D mutant cancer

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023224024
Dec 20233908
Jan 20244003
Feb 20244404
Mar 202480011
Apr 20245606
May 20248009
Jun 20245408
Jul 2024118014
Aug 20245203
Sep 20248405
Oct 202494011
Nov 20247409
Dec 202466014
Jan 202582010
Feb 202526011
Mar 2025105
Apr 20250011
May 2025009
Jun 2025005
Total12140180